Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection by Tewary, Poonam et al.
FEMS Immunology and Medical Microbiology 42 (2004) 241–248
www.fems-microbiology.orgVaccination with Leishmania soluble antigen and immunostimulatory
oligodeoxynucleotides induces specific immunity and protection
against Leishmania donovani infection
Poonam Tewary, Jayesh Mehta, Bindu Sukumaran, Rentala Madhubala *
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
Received 26 March 2004; received in revised form 27 May 2004; accepted 28 May 2004
First published online 11 June 2004Abstract
In this report, we investigated the effect of ODN containing immunostimulatory CG motifs as adjuvant with soluble antigen (SA)
from Leishmania donovani. BALB/c mice were vaccinated with the soluble antigen with or without CpG-ODN as adjuvant and then
challenged with L. donovani metacyclic promastigotes. CpG-ODN alone resulted in partial protection against challenge with L.
donovani. Immunization of mice with SA and CpG-ODN showed enhanced reduction in parasite load (60%) when compared to
SA (40%) immunized mice. Immunization with SA by itself resulted in a mixed Th1/Th2 response whereas co-administration of SA
with CpG-ODN resulted in a strong Th1 promoting isotype as they together promoted production of immunoglobulin G2a.
Leishmania-specific Th1 cytokine response was induced by co-administering CpG-ODN and SA as they together promoted pro-
duction of IFN-c and IL-12. In the present study, we demonstrate that immunostimulatory phosphorothioate-modified ODN are
promising immune enhancers for vaccination against visceral leishmaniaisis.
 2004 Published by Elsevier B.V. on behalf of the Federation of European Microbiological Societies.
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Leishmania are protozoan parasites that cause leish-
maniasis. Worldwide 10–15 million people are infected
with 2 million new cases each year and 1/10 of world
population is at risk of infection [1,2]. In a recent survey,
88 countries have been declared as leishmaniasis-en-
demic [3,4]. Leishmania donovani causes the severe, often
fatal disease visceral leishmaniasis (VL). The drugs that
are commonly used for the treatment of VL are penta-
valent antimonials. Lately there has been an increase in
the cases of leishmaniasis refractory to antimonial
treatment. Both human and mice develop protective* Corresponding author. Tel./fax: +91-11-26106630.
E-mail addresses: rentala@hotmail.com, madhubala@mail.jnu.
ac.in (R. Madhubala).
0928-8244/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.femsim.2004.05.008immunity after recovery from VL. While the develop-
ment of an anti-leishmanial vaccine appears feasible, it
remains to be accomplished.
Several candidate vaccine molecules have already
been evaluated in the mice model for leishmaniasis.
Considerable attention and efforts toward vaccination
against leishmaniasis have focused almost exclusively on
localized cutaneous disease [5–10]. Purified antigens,
subcellular fractions and avirulent parasites have been
used as potential vaccine candidates for cutaneous
leishmaniasis [11]. DNA vaccines have also been re-
ported to induce protective immunity in a variety of
experimental mouse models of infection through MHC
class I and class II-restricted T-cell responses [12–14].
While a substantial progress has been made no accept-
able anti-leishmanial vaccine exists against this infec-
tion. Presently there is no immunoprophylactic regimen
for leishmaniasis although several human trials usingation of European Microbiological Societies.
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bovis BCG are going on and initial results look prom-
ising [15]. The mouse models of infection with the pro-
tozoan parasite Leishmania major have helped to define
the Th1/Th2 model. Resistant C57BL/6 mice develop
protective Th1 responses that control infection, whereas
susceptible BALB/c mice are unable to control infection
due to an aberrant Th2 response [16,17]. Treatment and
vaccination that control the disease in susceptible mice
invariably promote Th1 responses over Th2 responses
[13,18,19]. There is no clear-cut immunological regime
for L. donovani. In mice infected with L. donovani, the
differential production of Th1 and Th2 does not control
the cure rate, although Th1 response correlates with
resistance to infection, the Th2 response does not de-
termine susceptibility [20]. In human disease, there is a
trend that both Th1 and Th2 responses against leish-
maniasis coexist in humans who have been cured of
visceral leishmaniasis [19,21].
Certain sequences of bacterial DNA and immuno-
stimulatory CpG DNA can modulate immune re-
sponse towards Th1 type [22–25]. The vertebrate
immune system can be activated by a variety of mi-
crobial components. Among these components, CpG
dinucleotides in particular base context are found in
bacterial DNA. Once recognized CpG motifs activate
a wide variety of innate immune responses [24,26].
This stimulatory capacity could be transferred to sin-
gle-stranded oligodeoxynucleotides (ODN) containing
specific sequences called as CpG-ODN. These CpG-
ODN directly activate monocyte, macrophages and
dendritic cells to secrete Th1-like cytokines (e.g. IL-12,
TNFa and IL-6 etc.) and express increased level of cell
surface co-stimulatory molecules [23,24,27–31]. These
CpG-ODNs have been used as adjuvants with a range
of protein vaccines and they facilitate a Th1 mediated
response, where as conventional protein vaccines alone
normally result in Th2 response with high titers of
neutralizing antibodies and poor cellular immunity
[31–38]. The potent Th1-like immune activation by
CpG-ODNs suggests a possible utility for vaccination
against leishmaniasis.
The role of CpG-ODN as a prophylactic vaccine
adjuvant has been studied using leishmanial proteins in
combination with CpG-ODN and has been reported
to confer some protection after a challenge with L.
major and L. donovani [37,39–41]. CpG-ODN is re-
ported to be more potent and durable than IL-12
protein in terms of immune and biological effects in
susceptible BALB/c mice after infection with L. major
[37].
In view of the potent in vivo effects on the cellular
immune response elicited by CpG-ODN, we have ex-
amined the protective efficacy of immunostimulatory
DNA or CpG motifs as immune adjuvants when ad-
ministered with L. donovani soluble antigen (SA) in amurine model system. We have also tested the effect of
CpG-ODN in combination with the SA on humoral and
cellular responses in BALB/c mice model of L. donovani
infection.2. Materials and methods
2.1. Animals
Female BALB/c mice (4–6 weeks old) were obtained
from the National Institute of Nutrition, Hyderabad,
India. All mice were used at ages ranging from 6 to 8
weeks. Animals were used in accordance to the institu-
tional guidelines and the relevant committee duly ap-
proved the use of animals for this work.
2.2. Parasite culture
Leishmania donovani strain AG83 (MHOM/IN/1983/
AG83) was maintained in BALB/c mice. Amastigotes
were isolated from spleens, and then transformed to
promastigotes in Medium 199 (Sigma, USA) supple-
mented with penicillin (100 U/ml Sigma, USA), 100 lg/
ml streptomycin (Sigma, USA) and 30% fetal calf serum
(FCS) (Biological Industries, Israel). Freshly trans-
formed promastigotes were cultured at 22 C in M199
medium and 10% heat-inactivated FCS and were used
for infecting BALB/c mice.
2.3. Source of soluble antigen
SA was prepared from stationary phase L. donovani
AG83 promastigotes. Cells were harvested by centrifu-
gation at 4000g for 15 min at 4 C and the pellet was
washed once with phosphate buffered saline (PBS), pH
7.2. The pellet was resuspended in PBS containing
protease inhibitors and lysed by sonication with six
pulses of 30 s each. The lysate was centrifuged at
17,000g for 15 min at 4 C and the supernatant was used
as the SA [42].
2.4. Oligodeoxynucleotides
A non-CpG-ODN 1911 (50-TCCAGGACTTTCCT-
CAGGTT-30) and a CpG-ODN 1826 (50-TCCAT-
GACGTTCCTGACGTT-30) were used in the present
study. All oligonucleotides were synthesized with a nu-
clease resistant phosphorothioate backbone (Micros-
ynth, Switzerland). The ODNs were resuspended in 10
mM Tris, pH 7.0/1 mM EDTA and stored at )20 C.
2.5. Immunization of mice and assessment of parasite load
Female BALB/c mice, 6–8 weeks of age, were used for
all immunizations (n ¼ 5 per group). Injections were
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cular injection 50 lg of SA and 10 lg each of ODN in
phosphate buffered saline (PBS) was used. SA was ad-
sorbed on alum. Control mice were injected with alum
diluted with PBS (final volume 100 ll). For the vacci-
nation studies, cell proliferation, cytokine production
and antibody response, mice were immunized twice at 2-
week interval with alum, SA, CpG-ODN 1826 alone, SA
plus CpG-ODN 1826, ODN 1911 alone and SA plus
ODN 1911. Mice were bled 2 weeks following the final
injection and sera from the mice in each group were
pooled. For the vaccination and protection studies, mice
were injected with alum, SA, CpG-ODN 1826 alone, SA
plus CpG-ODN 1826 and a booster were given at 4-
week interval. The mice were then challenged 2 weeks
after the final boost. For the challenge experiment,
1 108 stationary phase promastigotes of L. donovani
were injected intravenously via the tail vein in 100 ll of
PBS per mouse.
After 4 and 8 weeks of infection, mice were eutha-
nized and liver and spleen touch biopsies were micro-
scopically examined after fixing and staining the slides
with Giemsa. In order to quantitate levels of infection,
Leishman Donovan units (LDU) were calculated
as: (number of amastigotes/number of tissue nu-
clei)weight of tissue in milligrams. Assessment of
protection was performed using 10 mice per group. Five
mice from each group were sacrificed for determination
of parasitemia both at 4 and 8 weeks. The experiments
were repeated twice with similar results.
2.6. Spleen cell proliferation assay
Mice were immunized twice at 2-week interval with
50 lg SA, 10 lg of each of the ODNs either alone or in
combination with SA (in 100 ll of PBS). Two weeks
after the final injection, spleens were removed from mice
under aseptic conditions on a sterile dish containing
RPMI 1640 media. Single cell suspensions were pre-
pared by grinding the spleen with disk bottom of the
plunger of a 10-ml syringe. RPMI 1640 media (5–10 ml)
was added to the suspension and the contents were
mixed well. The dish was kept undisturbed for 2 min and
the clear supernatant was pipetted out slowly. Cells were
pelleted by centrifugation at 4 C at 250g (Sorvall RC-5
centrifuge, HB-4 rotor) for 10 min. Washing the pellet
once with 0.9% ice-cold ammonium chloride lysed ery-
throcytes. The remaining cells were resuspended to a
density of 2.5 106 cells/ml in RPMI 1640 containing
10% FCS and then divided into 200 ll aliquots (5 105
cells) in 96-well plates. Cells were incubated in the
presence or absence of SA (5 lg/ml) and incubated for 3
days at 37 C in an atmosphere containing 5% CO2.
Proliferation was measured by incorporation of 1 lCi of
3H-thymidine over the last 16 h of the culture. Amounts
of incorporation of 3H were measured by liquid scin-tillation counter. All assays were performed in triplicate,
with five mice representing each group.
2.7. Cytokine assays
The concentrations of IFN-c, IL-4 and IL-12 in
culture supernatants were determined as described
previously [39]. Briefly spleen cells were isolated from
mice co-injected with CpG-ODN 1826 or SA or a
combination of SA and CpG-ODN 1826, ODN 1911,
ODN 1911 plus SA 2 weeks after the final booster and
resuspended in RPMI 1640 medium supplemented with
10% FCS. Cells were then incubated in 96-well flat
bottomed plate (Nunc, Roskilde, Denmark) at a den-
sity of 5 105 cells per well and cultured with SA (5
lg/ml). After 48 h supernatants were collected and
diluted serially, and cytokine concentrations were
quantitated using enzyme linked immunosorbent assay
(ELISA). The assay was performed using Opt EIA Kit
(Pharmingen, SanDiego, CA) according to the manu-
facturer’s instructions.
2.8. Isotype analysis
Serum Ig isotypes were assayed by ELISA using 100
ng of SA per well, isotype-specific secondary anti-
bodies (biotinylated rabbit anti-mouse IgG2a, IgG2b
and IgG1) and streptavidin–horseradish peroxidase
(Pharmingen, San Diego, CA). In brief, 96-well plates
(Immulon-4, Nunc) were coated with 100 ng of SA in
50 ll of carbonate buffer, pH 9.2, and incubated
overnight at 4 C. The plates were washed thrice with
PBS containing 0.05% Tween 20 (PBST) and then
blocked by incubation for 2 h at 37 C in 200 ll of 5%
milk in PBST. Plates were then washed thrice with
PBST. Mouse sera (100 ll) diluted to 1:300–1:30,000
in PBST were added to the wells (except for experi-
mental blanks which were incubated with 5% milk in
PBST) and incubated at 37 C for 2 h. The plates were
washed thrice with PBST. The plates were then incu-
bated with 100 ll of 1:2000 dilution of biotinylated
antimouse IgG2a, IgG2b and IgG1 in PBST for 1 h at
37 C and washed again. The plates were then incu-
bated with 1:2000 of streptavidin conjugated horse-
radish peroxidase followed by washing thrice with
PBST. Color was developed by incubating with 100 ll
aliquot of o-phenylenediamine (5 mg/10 ml in 50 mM
citrate-phosphate buffer, pH 5.2) and 10 ll of 30%
H2O2 for 30 min. The reaction was then stopped with
50 ll of 2 N H2SO4. The absorbance at 490 nm was
determined using a model 7520 Microplate reader
(Cambridge Technology). All samples were run in
triplicate. Antibody levels were determined by com-
parison to a standard curve generated using a pooled
antiserum prepared from infected mice with high an-
tibody titer [26,40].
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Results from the different treated groups were com-
pared by Student’s t test. P values of <0.05 were con-
sidered statistically significant.3. Results
3.1. Splenocyte proliferation in mice co-injected with SA
and ODN
Splenocytes proliferation in mice injected with alum,
ODN 1911, SA plus ODN 1911, CpG-ODN 1826 and
CpG-ODN 1826 plus SA, was investigated in vitro as
described in Section 2. Splenocytes from mice injected
with ODNs did not exhibit increased proliferation of
cells when compared with the SA group. However, co-
administration of CpG-ODN 1826 and SA augmented
splenocyte proliferation in vitro by 1.76-fold when
compared to mice injected with SA alone (P < 0:001).
Co-administration of the control ODN 1911 (which has
composition matched to 1826 but lacks CpG dinucleo-
tide motif) resulted in only 1.03-fold increase in
splenocyte proliferation over the group treated with SA
(P < 0:05) (Fig. 1). This could probably be due to a non-
specifc response to the phosphorothioate background.
Non-CpG-ODN has been reported to induce B cell
proliferation and splenomegaly [40].
3.2. Isotype response by co-injection of ODN and SA
Antibody isotype profile provides a convenient mar-
ker of Th1 and Th2 CD4þ T-cell differentiation [43]. ToFig. 1. Splenocyte proliferation in mice co-injected with CpG-ODN
and SA. Mice were immunized twice at 2-week interval with 50 lg SA,
10 lg of each of the ODNs either alone or in combination with SA (in
100 ll of PBS). Spleens were collected as described in Section 2. Two
weeks following the final injection, splenocytes were stimulated with
SA and thymidine incorporation was determined. Delta-CPM repre-
sents the difference in counts compared with the corresponding non-
stimulated cells.compare IgG isotypes in non-protective vaccinated
mice, sera was collected from mice 2 weeks after the
second immunization and were assessed for IgG1 and
IgG2a and IgG2b. Immunization with SA antigen alone
gave a mixed Th1/Th2 response with more anti-SA an-
tibodies of IgG1 (Th2) than IgG2a (Th1) isotype (Fig.
2). Control ODN without CpG motifs (1911) did not
affect the isotype profile of sera from mice injected with
ODN 1911 and SA antigen. In contrast, mice injected
with SA antigen plus CpG-ODN 1826, the majority of
antibodies were IgG2a (Fig. 2).
3.3. Cellular response to SA and ODN in vaccinated mice
Susceptible BALA/c mice were co-injected intramus-
cularly with CpG-ODN 1826 or SA or a combination of
SA and CpG-ODN 1826, ODN 1911, ODN 1911 plus
SA. Two weeks later, spleens were removed and the
levels of IL-4, IL-12 and IFN-c production in spleno-
cytes from mice immunized with alum, ODN 1911, SA
plus ODN 1911, CpG-ODN 1826 and CpG-ODN 1826
plus SA were assayed in vitro. The splenocytes were
incubated in vitro in the presence SA (5 lg/ml). The
cytokines levels were measured by cytokine ELISA. The
levels of IFN-c, IL-12 and IL-4 produced in splenocytes
from mice immunized with soluble antigen are shown in
Fig. 3(a)–(c), respectively. There was an enhanced
production of IFN-c (3.5-fold) (Fig. 3(a)) and IL-12
(2.1-fold) (Fig. 3(b)) in mice injected with SA and CpG-
ODN 1826 when compared to groups where injections
were given individually. However, there was no signifi-
cant difference in the IL-4 levels in mice injected with
either SA or CpG-ODN 1826 (Fig. 3(c)). Non-CpG-
ODN did not result in enhanced production of IFN-c
(Fig. 3(a)). However, co-administration of ODN 1911Fig. 2. Relative anti-leishmanial IgG1, IgG2a and IgG2b levels in
immunized mice before challenge. Mice were bled 2 weeks after the
final injection. Antibody levels are expressed relative to a standard
pool as described in Section 2. Means and SE of Ig levels measured in
triplicates on at least five animals per group are shown. Immunization
was done using CpG-ODN 1826, ODN 1911, SA, or a combination of
CpG-ODN 1826 plus SA and ODN 1911 plus SA.
Fig. 3. Cellular immune responses in mice receiving SA and CpG-
ODN 1826 and ODN 1911. BALB/c mice were immunized twice at 2-
week interval with SA, 10 lg of each of the ODNs either alone or in
combination with SA (in 100 ll of PBS). Spleens were collected as
described in Section 2. Splenocytes were stimulated with SA and
concentration of released IFN-c, IL-12 and IL-4 in the culture su-
pernatants was determined. Data are represented as meansSE. Each
sample was examined in triplicate and these results are representative
of two experiments.
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pared to group where injection was given individually.
This increase is probably due to the SA. Thus immuni-
zation with soluble antigen and CpG-ODN led to
preferential production of IFN-c and IL-12 in spleen
cells stimulated with SA in vitro. It appears immuniza-
tion schedule preferentially induces Th1 type immune
responses. Relative antibody titers in groups immunized
with SA were nearly 7659 and CpG-ODN 1826 com-
bined with soluble antigen had a relative titer of 7968.
Relative antibody titers in animals receiving ODN
without CpG motifs (1911) alone or with alum were not
significantly different from those in respective control
groups (data not shown).
3.4. Protective immunity after immunization with CpG-
ODN and Leishmania soluble antigen
Since the in vitro splenocyte proliferation and cyto-
kine analysis data suggested that CpG-ODN 1826 re-
sulted in IFN-c dominant response as compared to
ODN 1911, we decided to determine whether co-injec-
tion of CpG-ODN 1826 with SA would confer pro-
tective immunity. Alum by itself did not result in
decreased parasite load when compared with mice in-
jected with PBS alone. Therefore, alum was used as a
control for all the experiments involving protection
studies. BALB/c mice vaccinated with SA, CpG-ODN
1826 alone or SA plus CpG-ODN 1826 resulted in
42%, 33%, 55% inhibition, respectively, of parasite load
in liver after 4 weeks (Fig. 4(a)). Parasite load was also
checked in the spleen. The parasite load decreased by
40%, 31%, 60% in BALB/c mice vaccinated with either
SA, CpG-ODN 1826 alone or SA plus CpG-ODN
1826, respectively (Fig. 4(b)). The inhibition of parasite
load after 8 weeks was 40%, 35% and 59% in liver and
46%, 34% and 61% in spleen in BALB/c mice vacci-
nated with either SA, CpG-ODN 1826 alone or SA plus
CpG-ODN 1826, respectively. A comparison of the SA
vaccinated and SA plus CpG-ODN 1826 vaccinated
mice shows a modifying role of the ODN on the im-
mune response to SA.4. Discussion
Earlier studies have demonstrated that plasmid DNA
immunostimulatory sequences promote Th1 responses
[32]. The ability of CpG-ODN to induce both innate and
adaptive cellular immune response has made it a po-
tential treatment and/or prophylactic vaccine adjuvant,
respectively, for disease requiring cellular immunity. The
strong activating effect of CpG DNA on B cells, as well
as the induction of cytokines that could have indirect
effects on B cells via T-helper pathway, suggests utility
of CpG-ODN as a vaccine enhancer [24,26]. In the
Fig. 4. Infection levels of vaccinated mice following challenge with L. donovani. BALB/c mice were immunized with alum, CpG-ODN 1826, SA and
SA plus 1826 twice at 4-week intervals. Two weeks following the final injection, the mice were challenged intravenously with 1 108 L. donovani
promastigotes. Four and 8 weeks after challenge infection, mice were killed and LDU was calculated from liver (a) and spleen smears (b). The mean
LDUSE is shown (n ¼ 5 mice per group). Means which differ significantly from that of the corresponding alum control are indicated by: +,
P < 0:005; ++, P < 0:0005; ··, P < 0:0001 or ·, P < 0:001.
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munostimulatory phosphorothioate-modified ODN as
an adjuvant with a leishmanial SA can modulate leish-
manial-specific immunity towards a protective response
in mice.
This study demonstrates that the effects of immuno-
stimulatory ODN as an adjuvant were partial and lim-
ited, as protection was only 33% in mice 4 weeks after
challenge. The greater efficacy of the leishmanial soluble
antigen plus CpG-ODN was observed. CpG-ODN had
an in vivo impressive effect in modulating the response
to vaccination with soluble antigen. Administration of
SA alone or with CpG-ODN resulted in 40% and
60% reduction in the parasite load in liver at 8 weeks
after challenge, respectively.
Earlier observations have also shown that susceptible
BALB/c mice when immunized with Leishmania SA with
or without CpG-ODN as adjuvant and then challenged
with L. major metacyclic promastigotes showed a highly
significant reduction in swelling when compared to SA-
vaccinated mice and enhanced survival when compared
to unvaccinated mice [39,40]. CpG-ODN, when used as
a vaccine adjuvant with either a recombinant protein or
heat killed leishmanial antigen, can induce long-term
protection against an intracellular infection in a CD8þ-
dependent manner [37]. Individual mice immunized with
ODNs and Leishmania lysate demonstrated Leishmania-
specific lymphocyte proliferation and IFN-c protection
in response to parasites in vitro [39]. The mechanism by
which CpG-ODN mediate their function in vivo is by
enhancing antigen presenting cells (APC) function
through toll-like receptor 9, thereby augmenting both
the activation and maturation of dendritic cells (DC) as
well as the induction of proinflammatory cytokines [43].
CpG-ODN induction of IL-12, IL-18 and other soluble
mediators from activated DC is likely to result in a more
physiological cognate interaction between the DC andT-cells, resulting in both a qualitative and quantitatively
different type of CD4þ and CD8þ T-cell response [37].
It is well established that CpG-ODN are potential
inducers of Th1 responses, which is consistent with our
findings that mice vaccinated with ODN plus SA had
striking enhancement of the production of IFN-c and
IL-12. Use of CpG-ODN along with SA resulted in al-
most additive effect in the production of cytokines in
vitro. Immunization with SA antigen alone gave a mixed
Th1/Th2 response with more anti-SA antibodies of IgG1
(Th2) than IgG2a (Th1) isotype. In contrast, in mice
injected with SA antigen with CpG-ODN 1826, the
majority of antibodies were IgG2a.
Thus, the immunostimulatory effect of CpG-ODN
can be utilized to create a protective vaccine when given
in combination with specific antigen from L. donovani in
mice model system. Our results in murine L. donovani
model, shows promising role of ODN as adjuvants in
combination with Leishmania-specific antigen and can
be exploited to create a protective vaccine. Additionally,
CpG-ODN may be very useful for eliciting an enhanced
cellular and humoral response and increasing the effi-
cacy of individual antigens that induce partial but in-
complete protection. Further studies would be required
to evaluate the effect of different doses of CpG-ODN to
further improve the efficacy of the present vaccine for
visceral leishmaniasis in a murine model.Acknowledgements
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